+Compare
HALO
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
4.98B

HALO Price Prediction, Halozyme Therapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for HALO with price predictions
08:00 PM EDT Oct 01, 2023

Momentum Indicator for HALO turns negative, indicating new downward trend

HALO saw its Momentum Indicator move below the 0 level on September 26, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In of the 93 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

HALO moved below its 50-day moving average on September 05, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HALO crossed bearishly below the 50-day moving average on September 11, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HALO entered a downward trend on September 20, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HALO's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

HALO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.333) is normal, around the industry mean (22.679). P/E Ratio (22.472) is within average values for comparable stocks, (131.550). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.091). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (6.793) is also within normal values, averaging (308.078).

A.I. Advisor
published Earnings

HALO is expected to report earnings to 74 cents per share on November 07

Halozyme Therapeutics HALO Stock Earnings Reports
Q3'23
Est.
$0.74
Q2'23
Beat
by $0.14
Q1'23
Beat
by $0.08
Q4'22
Beat
by $0.18
Q3'22
Beat
by $0.42
The last earnings report on August 08 showed earnings per share of 74 cents, beating the estimate of 60 cents. With 401.55K shares outstanding, the current market capitalization sits at 4.98B.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 407.89B. NVO holds the highest valuation in this group at 407.89B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was 18%, and the average quarterly price growth was 23%. SLNO experienced the highest price growth at 494%, while RNAZ experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -29%. For the same stocks of the Industry, the average monthly volume growth was 73% and the average quarterly volume growth was 28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12390 El Camino Real
Phone
+1 858 794-8889
Employees
393
Web
https://www.halozyme.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ARCM99.570.02
+0.02%
Arrow Reserve Capital Management ETF
IRBA8.77-0.06
-0.63%
iM RBA Responsible Global Allocation ETF
ALTL34.20-0.25
-0.72%
Pacer Lunt Large Cap Alternator ETF
SPFF8.65-0.12
-1.41%
Global X SuperIncome™ Preferred ETF
IJS87.90-1.32
-1.48%
iShares S&P Small-Cap 600 Value ETF

HALO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
-1.26%
AXON - HALO
47%
Loosely correlated
-1.43%
MDGL - HALO
46%
Loosely correlated
-1.81%
MNKD - HALO
45%
Loosely correlated
-2.42%
FGEN - HALO
38%
Loosely correlated
-5.83%
ADMA - HALO
35%
Loosely correlated
-1.26%
More